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ABSTRACT 
Research findings have suggested no differences in growth among term infants 
fed DHA supplemented formulas.  Studies have found maternal smoking decreases length 
and increases weight of children.  No studies have analyzed maternal smoking and DHA 
supplementation on growth of term infants to age six.  
The study aim was to determine if DHA supplementation in formula consumed 
from birth to one year and maternal smoking affects growth of children through six years.  
Anthropometric measures and maternal characteristics were collected at 16 study visits 
from birth to six years.   
 DHA supplementation increased weight-for-age and height-for-age but not BMI-
for-age percentiles from two to six years.  Maternal smoking during pregnancy increased 
weight-for-age, height-for-age, and BMI-for-age percentiles.  Weight-for-age was not 
affected by age, however, BMI increased by 6.5% per year.  Energy intake was not 
related to DHA or maternal smoking during pregnancy, suggesting effects on body size 
and fatness were unrelated to energy intake differences.  
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Chapter 1 
Introduction 
Docosahexaenoic acid (DHA) is a long chain omega-3 polyunsaturated fatty acid 
essential for visual, cognitive, and central nervous system development in infants (1, 2).  
DHA was added to infant formulas in the United States in 2002 (3).  A review of 13 
randomized studies in preterm infants and 19 randomized studies in term infants 
determined omega-3 fatty acids may decrease growth of preterm and term infants, 
dependent on the experimental conditions, but the effects on growth appeared minimal 
and the clinical relevance was questioned (4).  Three indicate DHA-supplemented 
formula fed to preterm infants improves weight gain (2, 5, 6).  Six studies report the 
effects of DHA-supplemented formula fed to term infants and find no differences in 
weight or length (7-12).    
We took advantage of a cohort of children who were evaluated every six months 
between birth and six years of age and who were provided one of four levels of DHA in 
formula to evaluate infant and child growth and BMI.  We collected detailed records of 
dietary intake, formula tolerance, and anthropometrics and maternal characteristics 
including weight and smoking status.  An earlier preliminary analysis of growth during 
the first four years of life in this cohort indicates that maternal smoking status does not 
affect weight-for-age percentiles but significantly affects length- and height-for-age 
percentiles in children through four years of age (p=0.043).  Infants and children born to 
women who smoked were shorter and had higher BMI-for-age percentiles compared to 
those born to non-smoking women.  No significant effects were found between infants 
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fed various percentages of DHA-supplemented formula and weight-for-length and BMI-
for-age percentiles through age four (13). 
Justification for Further Investigation 
The study conducted at the University of Kansas Medical Center (13) is the only 
study that has tracked the longitudinal growth of infants fed DHA-supplemented formula 
and the effects of maternal smoking status through four years of age.  Growth data are 
now available for children through six years of age, and we have the data to extend the 
evaluation to school age.  Six studies have measured weight and length in term infants (7-
12).  This is the first dose-response study of DHA to determine the longitudinal growth of 
term infants.  Because a high proportion of women smoked prior to or during pregnancy, 
the cohort offers the possibility to evaluate maternal smoking status and growth.   
Statement of Purpose 
 The study has two primary objectives.  The first objective is to determine if the 
concentration of DHA in a formula consumed from birth to 12 months of age affects 
growth from birth to six years of age, particularly in weight-for-length (for children 
younger than two years of age) and BMI-for-age (for children between two and six years 
of age).  A second objective is to determine if maternal smoking during pregnancy affects 
BMI-for-age percentiles. 
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Primary Research Questions 
1. Is DHA intake in infant formula consumed from birth to one year of age related to 
body mass index (BMI) percentiles (two to six years)?  
2. Does maternal smoking during pregnancy affect BMI of children two to six years 
of age? 
Secondary Research Question 
Is energy intake related to BMI? 
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Chapter 2 
Review of Literature 
Infant and Child Growth Patterns 
Infants and children grow at various rates from birth through adolescence.  
Immediately after an infant is born, he or she loses five to ten percent of his or her body 
weight (14).  After the weight loss period, an infant’s length and weight increase rapidly.  
It is normal growth for weight to double by four to six months of age.  Typically, an 
infant’s BMI increases and then decreases until four to five years of age (15, 16).  By age 
four, a child’s height is typically twice the birth length, and weight increases by six grams 
per day.  At age five, a child should gain four to five pounds and grow two to three inches 
per year.  School-aged children, six to twelve years old, will display differences in 
weight, height, and body composition.  Variation in growth at all ages reflects a 
combination of genetics, nutrition, and exercise (14).  
Stable growth continues from two to ten years of age, but the rate of growth and 
maternal weight may predict children becoming overweight or obese in the future.  
Children who have mothers who are overweight are at risk of becoming overweight, and 
low maternal weight is a predictor of underweight in children (17).  A physiological 
adiposity rebound occurs when infant’s and children’s BMI rises for a long period of 
time.  When BMI rises before the age of four or five years, early adiposity rebound 
occurs and results in increased risks for obesity as the child ages (15, 16).   
Brune et al. (17) suggests BMI development occurs in phases.  During an infant’s 
first month of life, BMI sharply increases.  There is another increase in BMI between 
eighteen months and five years of age (16).  At this time, BMI increases in overweight 
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children and children experience another rapid weight gain, whereas children who are 
underweight remain at low weights and BMI declines.  After age six, children with a high 
or low BMI typically remain stable (17).  
Growth Charts for Infants and Children  
Normal growth is exponential (14).  The Centers for Disease Control and 
Prevention (CDC) created growth charts.  The updated 2000 CDC growth charts are used 
by pediatricians, nurses, dietitians, and parents to assess and illustrate infant and child 
growth (18, 19).  The charts are based on 82 million birth weights, 445,000 birth length 
measurements, and data from the National Health and Nutrition Examination Survey 
(NHANES), a cross-sectional survey of health and nutrition among people in the United 
States.  Survey results from NHANES I (1971-1974), NHANES II (1976-1980), 
NHANES III (1988-1994), and the CDC Pediatric Nutrition Surveillance System 
(PedNSS) from 1975 to 1995 assisted in creating the growth curves (20).   
The 2000 CDC growth charts include normal values for length or stature, weight, 
and BMI from birth through 20 years of age expressed as percentiles for each gender to 
account for differences in growth between males and females.  The CDC charts measure 
head circumference-for-age and weight-for-length for males and females younger than 
two years of age (20).  The charts also include measurements of weight-for-age and 
stature-for-age for boys and girls two years of age and older.  BMI-for-age charts were 
added to the 2000 CDC growth charts for children and are used between ages two and 20 
to assess weight-for-stature and to screen children at risk for low growth or excess body 
fat (21).  BMI is calculated as body weight in kilograms (kg) divided by height in meters 
squared (m)
2
 and is used to determine if children and adults are underweight, overweight, 
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or obese but can only be used starting at age two when height is more accurately 
measured (21).   
To assist health professionals in determining growth risks, percentile ranges have 
been developed for weight-for-length and BMI-for-age.  A weight-for-length or BMI-for-
age percentile below the fifth percentile is considered underweight.  Percentiles between 
the 5
th
 and 85
th
 are considered healthy.  A percentile between the 85
th
 and 95
th
 percentile 
is considered overweight, and a percentile above the 95
th
 percentile is classified as obese 
(21).  The CDC growth charts are used for clinical assessments of children but are not 
used as the only diagnostic tool (18).   
Diet and nutrition of the mother, infant, and child are determinants of growth and 
the likelihood for children to become overweight or obese in the future (22, 23).  One 
nutrient that influences growth of infants and children is docosahexaenoic acid (DHA) (2, 
5-12).    
Docosahexaenoic Acid (DHA)  
Definition and Mechanisms  
Docosahexaenoic acid (DHA; 22:6n-3), an omega-3 long chain polyunsaturated 
fatty acid, is important for visual, cognitive, and central nervous system development in 
infants (1, 2).  The omega-3 fatty acid alpha-linolenic acid (ALA; 18:3n-3) forms 
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA) through 
desaturation by a microsomal enzyme system, and the omega-6 fatty acid linoleic acid 
(LA; 18:2n-6) forms arachidonic acid (AA or ARA; 20:4n-6) by desaturation (24).  DHA 
affects cell membranes and signals between cells and genes that play a role in the growth 
of cells (2).  DHA accumulates in the brain mainly during the last trimester of gestation 
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and in the infant’s first two years of life, but this is influenced by the mother’s DHA 
status and the DHA consumed postnatally (24, 25).  
Dietary DHA Recommendations   
 The Institute of Medicine (IOM) set an Adequate Intake (AI) for ALA as 0.6% of 
the energy based on the amounts needed to prevent deficiency and promote growth and 
development (26).  The IOM recommendations for the AI of ALA are 0.5 g/d for infants 
and 1.1 g/d for women (27).  No requirement has been determined for DHA and EPA; 
however, the National Academies indicates 10% of the Acceptable Macronutrient 
Distribution Range (AMDR) for ALA can be consumed as DHA and EPA (26).  Other 
experts recommend that pregnant and lactating women consume at least 200 to 300 mg of 
DHA per day (26).  The same experts recommend that infant formula contain between 
0.2 and 0.5% weight of total fatty acids with DHA higher than the level of ARA (26).   
DHA in Infant Formula 
In the past, infants have had to synthesize long chain polyunsaturated fatty acids 
(LC-PUFA) from fatty acids in infant formula.  The European Society for Paediatric 
Gastroenterology and Nutrition suggested low birth weight infants be fed formula 
supplemented with alpha-linolenic and linoleic acids, similar to levels in breast milk.  
Conversion of ALA to DHA is limited during infancy; thus, alpha-linolenic acid in 
formula may not be needed for DHA (24, 28).  DHA and ARA were added to infant 
formulas in the United States in 2002 (3).  Because DHA and ARA levels are similar in 
breast milk and formula, infants who are formula fed should receive enough of these fatty 
acids for brain growth and development (6).  
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Effects of DHA on Growth  
Research on formula supplemented with DHA and the effects on preterm infant 
growth is inconclusive.  A review of 13 randomized studies in preterm infants and 19 
randomized studies in term infants determined omega-3 fatty acids may decrease growth 
of preterm and term infants, dependent on the experimental conditions, but the effects on 
growth appeared minimal and the clinical relevance was questioned (4).  O’Connor et al. 
(5), found that preterm infants fed formula supplemented with DHA and ARA until at 
least six months corrected age (CA) had higher growth and visual acuity development.  
Similarly, Innis et al. (6) found that preterm infants fed DHA and ARA gained more 
weight from 40 to 57 weeks post menstrual age compared to infants fed formula without 
DHA and ARA (34.7 grams per day (g/d) vs. 30.7 g/d, respectively; p=0.004); however, 
rate of weight gain of preterm infants fed formula with DHA (33.2 g/d) was not 
significantly different among infants fed formula with DHA and ARA or formula without 
DHA or ARA (6).  From birth to four months of age, the weight-to-length ratio was 
higher in infants who consumed formula with DHA and ARA compared to formula with 
only DHA.  However, at two months of age, infants who received DHA and ARA-
supplemented formula had significantly higher body weight, length, and weight-to-length 
ratios compared to infants fed formula without DHA and ARA (6).   
Groh-Wargo et al. (2) observe that preterm infants fed DHA and ARA have 
significantly more lean body mass at 12 months corrected age compared to infants fed 
formula without DHA and ARA.  The infants fed DHA and ARA also have significantly 
lower fat mass compared to infants not fed DHA and ARA (p<0.05) (2).  At 12 months 
CA, infants had greater lean body mass after receiving formula with DHA and ARA from 
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fungal oil and fish oil (6.83 kilograms [kg] ± 0.13) and DHA and ARA with egg-derived 
triglyceride and fish oil (7.00 kg ± 0.14) compared to infants who had consumed formula 
without DHA and ARA (6.53 kg ± 0.15).  DHA and ARA supplemented infants also had 
lower fat mass when consuming formula with DHA and ARA from fungal oil and fish oil 
(2.60 kg ± 0.12) and DHA and ARA from egg-derived triglyceride and fish oil (2.60 kg ± 
0.13) compared to infants who consumed the unsupplemented formula (3.07 kg ± 0.14), 
(p<0.05) (2).   
  Studies on the effects of formula supplemented with DHA on term infant growth 
are limited.  In a study of term infants, Makrides et al. (7) fed infants formula 
supplemented with either DHA or DHA and ARA.  No differences were found in weight 
or length between term infants fed formula with DHA, DHA and ARA, or without DHA 
or ARA.  However, negative effects on infant length were found with maternal smoking, 
regardless of formula (7).  Similarly, Auestad et al. (8) examined term infants and found 
no difference in weight or length among infants fed formula with DHA and ARA or 
without DHA and ARA.  Male infants fed formula with DHA and ARA, however, gained 
more weight between enrollment and four months of age compared to infants receiving 
no DHA and ARA in the formula, but this difference in weight gain did not persist at 12 
months (8).  Two other studies by Auestad et al. (10, 11) also found no differences in 
weight or length of term infants through one year of age and through 39 months of age 
when formula was supplemented with DHA, DHA and ARA, or unsupplemented.  In 
contrast to these findings, one study found term infants given formula supplemented with 
DHA and ALA had significantly lower body weight at four months of age (p=0.02) when 
high ALA (3.2%) was in the formula compared to child given the lowest amount of ALA 
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(0.4%).  These infants had somewhat lower weight at eight months of age compared to 
three other formula groups with 0.4%, 1.0%, and 1.7% ALA, respectively, but the 
differences were not significant (9).    
Effects of Maternal Smoking on Growth of Infants and Children 
Length and height of infants and children is affected by maternal smoking during 
pregnancy.  Mothers who smoked throughout gestation had children with lower length at 
birth and who were shorter in height through age eight (29).  Koshy et al. (30) found 
children had lower average height-for-age z-scores when their non-smoking mothers 
were exposed to passive cigarette smoke during gestation and the father smoked 
compared to mothers not exposed to any smoke (p<0.01).  If women were heavy smokers 
themselves, the difference was 2.76 times greater (30).  Shorter stature in children has 
also been associated with paternal smoking (p=0.009).  When both the mother and father 
were heavy smokers, children’s chances of a shorter stature were increased 4.28 times 
(p=0.012) (30).  
Maternal smoking during gestation also affects children’s weight.  The prevalence 
of being overweight was significantly higher in children born to mothers who smoked 
during gestation compared to those born to mothers who never smoked (p<0.05) (31).  
Koshy et al. (30) found a higher prevalence of obesity in male (p=0.029) and female 
(p=0.014) children born to mothers who smoked at any point during pregnancy compared 
to mothers who had not smoked.  The same researchers reported the odds for risk of 
obesity increased by 1.61 (p=0.002) in children born to mothers who smoked (30).  
Holmo-Fasting et al. (32) determined the odds ratio for children to become overweight 
decreased from 2.83 (95% CI: 1.13, 7.10) to 1.29 (95% CI: 0.62, 2.67) when mothers 
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stopped smoking during gestation.  In contrast, Chen and colleagues (29) report that prior 
to the age of eight, children had only moderately increased risks of becoming overweight 
from maternal smoking during gestation.   
Timing of Maternal Smoking during Gestation on BMI 
The timing and duration of maternal smoking during gestation may affect a 
child’s weight later in life.  Mendez et al. (31) found mothers who smoked only during 
the first trimester of gestation had the highest prevalence (39.7%) of overweight children.  
Maternal smoking in the first trimester doubled the odds of children between five and 
seven years of age becoming overweight (31).  The researchers also found mothers who 
smoked only during the first trimester were more likely to have a child become obese 
later in life than mothers who continued smoking during the second and third trimesters.  
However, Chen et al. (29) found when mothers smoked during the third trimester of 
gestation, children had a greater risk of becoming overweight in the future compared to 
children of women who smoked only during the first trimester.  Another study reported 
an increase in BMI and total fat mass in infants was associated with mothers who smoked 
during any point of gestation (33).   
Children’s BMI is affected when women smoke during pregnancy.  A study by 
Holmo-Fasting and colleagues (32) found BMI was three percent lower in children born 
to mothers who never smoked compared to those who stopped smoking in early 
gestation.  The researchers also found a 0.47 (95% CI: 0.10, 0.84) higher mean difference 
in BMI in children born to women who smoked and an adjusted odds ratio of 2.83 (95% 
CI: 1.13, 7.10) of becoming overweight by age four compared to those who did not (32).   
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In contrast, the same researchers reported that BMI decreased by four years of age 
in children born to smoking mothers when maternal smoking duration diminished in early 
gestation.  At four years of age, BMI levels were similar for children of non-smoking 
mothers and those who stopped smoking early in gestation (BMI 15.81 kg/m
2
 vs. 15.84 
kg/m
2
, respectively).  These results suggest that BMI does not significantly differ 
between children born to mothers who never smoked and children of mothers who 
stopped smoking during pregnancy (32).  Children of women who smoked throughout 
pregnancy, however, had a BMI of 16.09 kg/m
2 
by age four.  In contrast, Gilman et al. 
(34) did not find an association between children’s BMI at seven years of age.   
Catch-up Growth 
The rate of weight gain in early life may affect weight later in life.  Leary et al. 
(33) associated rapid weight gain early in life with future overweight status regardless of 
birth weight.  Infants born to mothers who smoked experienced rapid catch-up growth 
during the first year after being born at low birth weights, and at age five, children had 
comparable or higher body weights than children born to non-smoking mothers.  The 
rapid growth predicted increased risk of developing diabetes, hypertension, and 
cardiovascular disease as adults (29).  
DHA Levels in Infants Born to Mothers Who Smoke 
Maternal smoking during gestation may alter DHA levels and fat mass in infants.  
One study found lower DHA levels and lower DHA to ALA ratios in infants born to 
women who smoked during pregnancy (35).  When mothers smoked only during the first 
trimester of gestation, infants had moderate levels of DHA and ALA.  The same 
researchers suggested that some of the effects of smoking on growth might be due to a 
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limited placental transport of DHA to the fetus with maternal smoking.  While this theory 
has not been tested, an increase in BMI and total fat mass in infants was associated with 
mothers who smoked any time during gestation (35). 
Potential Mechanisms of Smoking Affecting Growth of Infants and Children  
Fetal metabolism changes when women smoke during pregnancy.  Children born 
to mothers who smoke during pregnancy may have growth restrictions and alterations in 
appetite and metabolism from nicotine and carbon monoxide exposure (29).  Koshy et al. 
(30) indicate that paternal smoking can affect growth after birth and influence childhood 
appetite as well.  Infants may adapt to smoking-related hypoxia and alter their appetite, 
similar to adjustments when people stop smoking and experience nicotine withdrawal 
(36, 37).  Because nicotine suppresses appetite, infants feed more after birth compared to 
before birth due to less exposure to nicotine (38).  Infants exposed to nicotine may also 
have an increased number of fat cell abnormalities related to changes in adipose tissue 
(30).  Length and height differences in infants and children born to mothers who smoked 
during gestation may be the result of alterations in body fat, appetite control (39), and 
leptin and ghrelin responses (40, 41). However, Mendez et al. (31) claims there are no 
known mechanisms for how smoking during gestation affects weight gain and growth 
later in childhood. 
Conclusion 
The results of infant formula supplemented with DHA and ARA on growth of 
children zero to six years of age are inconsistent, although more suggest higher growth 
compared to unsupplemented children (2, 5, 6).  Further research is warranted.  Studies 
have indicated that children born to mothers who smoke during pregnancy are more 
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likely to have higher body weights and body mass indices with age (29-31, 33).  The 
effect of maternal smoking status in conjunction with formula supplemented with DHA 
in relation to growth of children later in life has not been evaluated.  Analyzing the effect 
of maternal smoking and formula supplemented with DHA could help to determine if 
either DHA intake or maternal smoking influences children’s weight, height, and BMI. 
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Chapter 3 
Methods 
The DIAMOND (DHA Intake And Measurement Of Neural Development) study 
was a double-blinded, 2-phase, randomized, controlled, parallel-group, prospective trial 
to observe infants from birth to 18 months of age.  The DIAMOND study was designed 
to determine the effects of infant formula supplemented with long-chain polyunsaturated 
fatty acids on visual and cognitive development in term infants.  The primary objective of 
the study was to determine visual evoked potential acuity with secondary objectives that 
examined formula acceptance and tolerance, weight gain, length gain, head 
circumference gain, fatty acids and vitamin E, stereoacuity, cognitive development, and 
language development to 18 months of age.  After 18 months, children were reenrolled 
and followed with similar assessment from age two to six years.    
Ethics 
 The second phase of the study, from two to six years of age, was approved by the 
Institutional Review Board Ethics Committee and the Human Subjects Committee of the 
University of Kansas Medical Center in Kansas City, Kansas, as a project (HSC #10205) 
stemming from the parent trial (HSC #9198): The DIAMOND Study: A Double Masked, 
Randomized Controlled Clinical Trial of the Maturation of Infant Visual Acuity as a 
Function of the Dietary Level of Docosahexaenoic Acid.  Written informed consent was 
obtained from each subject’s parent(s) or guardian(s), and a copy of the signed written 
informed consent form was provided to them prior to participation in the clinical trial.  
Protected Health Information (PHI) was protected by having all information that could be 
linked to the subject in a locked file cabinet in a restricted access corridor of Smith West, 
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University of Kansas Medical Center.  Only study personnel needing direct access to PHI 
were allowed access to collected data.  All subject records were coded with initials and 
numbers.  No information or data were stored on a laptop or on the internet to prevent 
identification of subjects.  The study was unblinded to the study Principal Investigators 
(PIs) after all children reached 18 months of age, but personnel with access to subjects 
did not know their assignment until all children reached six years of age.   
Research Setting and Subject Selection 
 The recruitment and enrollment of study subjects took place in prenatal clinics at 
two hospitals: Truman Medical Center (TMC) in Kansas City, Missouri, and the 
University of Kansas Medical Center (KUMC) in Kansas City, Kansas from September 
2003 through September 2005.  The study was conducted from September 2003 through 
October 2011.   
To be included in the study, infants needed to be healthy, singleton-birth term 
infants 37 to 42 weeks gestation, weighing between 2490 and 4550 grams at birth, and 
formula-fed.  Infants were excluded if they received human breast milk within 24 hours 
of randomization or had diseases or abnormalities that could affect growth, development, 
vision, or cognitive function; or who did not tolerate cow’s milk infant formula or had 
poor intake of formula.  Infants were also excluded if they were born to mothers with 
HIV, renal disease, hepatic disease, diabetes, substance abuse, or other chronic illnesses.  
A total of 70 children were followed from birth to six years of age and were 
assessed at 6 weeks, 4 months, 6 months, 9 months, 12 months, 18 months, 2 years, 2.5 
years, 3 years, 3.5 years, 4 years, 4.5 years, 5 years, 5.5 years, and 6 years.  The first 
phase of the DIAMOND study enrolled 159 subjects followed from birth to 18 months of 
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age and were seen at 6 weeks, 4 months, 6 months, 9 months, 12 months, and 18 months.  
Children whose parents consented to the DIAMOND follow-up study (phase 2) were 
followed for growth and developmental outcomes to six years of age and were seen at 2 
years, 2.5 years, 3 years, 3.5 years, 4 years, 4.5 years, 5 years, 5.5 years, and 6 years. 
Infant Formula and Randomization 
Infants enrolled in the study were assigned to one of four formulas.  The formulas 
used in the study were cow’s milk-based with the same nutrient levels, except the amount 
of DHA and ARA.  The control group formula did not contain DHA or ARA (group 1).  
Formula group 2 had 0.32% fatty acids from DHA, containing 17 milligrams (mg) per 
100 kilocalories (kcal), formula group 3 contained 0.64% DHA with 34 mg/100 kcal, and 
formula group 4 had 0.96% DHA with 51 mg/100 kcal.  The DHA was from an algal 
source.  All three DHA supplemented formulas contained 0.64% (34 mg/100 kcal) ARA 
from a fungal source.   
Subjects were randomized by the study sponsor, Mead Johnson & Co., 
Evansville, Indiana, using a random-number generator function.  Formula was packaged 
by the sponsor and only identified by color code.  Each formula had two different color 
codes for a total of eight codes for study formulas.  Groups were balanced for gender 
with each gender having an independent randomization.  Envelopes prepared for each 
gender contained the code of the study formula to be assigned based upon the randomized 
lists.  Following enrollment, the next sequential numbered envelope for a male or female 
was opened.  Formula was provided for the infants at clinic visits, and study personnel 
were not aware of which formulation the infants received.   
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The formula was fed to infants until one year of age, and parents were encouraged 
to feed only formula for the first four months of age.  After four months, infants could be 
fed additional foods as determined by physicians, but parents were told not to feed any 
DHA supplemented or enriched foods until one year of age. 
Data Collection  
Data were collected and entered into Microsoft Excel spreadsheets by trained 
research staff and registered dietitians.  Anthropometric measures and dietary intakes 
were assessed at each clinic visit occurring at 6 weeks, 4 months, 6 months, 9 months, 12 
months, 18 months, 2 years, 2.5 years, 3 years, 3.5 years, 4 years, 4.5 years, 5 years, 5.5 
years, and 6 years.  Formula intake data were collected at each clinic visit from six weeks 
through 12 months of age. 
Demographic Data  
Demographic data and maternal characteristics were collected through interviews 
and questionnaires.  Information self-reported by mothers of infants enrolled in the study 
included maternal weight, height, education level, race and ethnicity, smoking status 
prior to and during pregnancy, number of packs of  cigarettes smoked per day, and pack 
years of smoking, among other information.  See appendix A for the demographic data 
collection forms.  
Anthropometric Data 
Birth weight, length, and head circumference were obtained within the first nine 
days of life from the participant’s birth records.  From six weeks through six years, 
weight was measured on a calibrated, standardized pediatric scale.  A length board was 
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used to measure recumbent length, a stadiometer to measure height, and a flexible, non-
stretchable vinyl measuring tape was used to measure head circumference.   
Body weight was recorded to the nearest gram (for infants and children less than 
18 months of age) or ounce (2 to 6 years of age) with infants only wearing a dry diaper 
and children wearing no shoes.  Until children were two years of age, body length was 
measured once to the nearest tenth of a centimeter with the subject held in a recumbent 
position with one person holding the subject’s head to contact with the fixed headboard 
and a second person holding the subject’s knees flat and feet with the toes pointing 
directly upward, while moving the footboard firmly against the subject’s heels.  Height 
was measured once using a stadiometer at each visit between two and six years of age 
with the subject’s feet flat on the floor against the wall, looking straight ahead, without 
shoes.  Head circumference was measured to the nearest tenth of a centimeter using a 
flexible, non-stretchable vinyl measuring tape at the highest occipital circumference (18-
21).  See appendix B for the anthropometric data collection form.  
All anthropometric measures from each clinic visit were used to calculate the 
Centers for Disease Control growth percentiles using Epi Info. software (18-21).  The 
weight-for-length and length-for-age percentiles were calculated for subjects less than 
two years old, and stature-for-age and BMI-for-age percentiles were calculated for 
subjects between two and six years of age.   
Weight, length/height, and head circumference measures were entered into the 
Epi Info. software program to obtain weight-for-age, length/stature-for-age, weight-for-
length, and BMI-for-age percentiles.  At age two, 54 of 79 total subjects were 23 months 
of age and not exactly 24 months of age by their estimated delivery date (EDD).  To 
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accurately calculate the stature-for-age percentiles at age two, the 54 children were 
rounded to exactly 24 months of age in Epi Info.  Height was not recorded as length and 
was not recumbent.  Tests of growth percentiles with 24 months of age compared to 23 
months were done by a t-test, and no significant difference was found (p=0.9).  Except 
for stature-for-age, the exact age of the child was used and only the 24 month old 
children’s data were adjusted.  Weight-for-length percentiles were calculated for all ages, 
however if the child’s height was greater than 121 centimeters (cm), the stature-for-age, 
height z-scores, weight-for-length percentiles, and weight-for-length z-scores were not 
able to be calculated.  This resulted in the omission of weight-for-length percentiles and 
z-scores for one five year old child, four 5.5 year old children, and 11 six year old 
children.   
 For subjects missing one time point, the weight and length measurements were 
imputed.  To impute data, a conversion factor was calculated from the average gain of all 
subjects before the missing time point and after the missing time point and then used to 
calculate the individual's data point.  A total of 14 children were missing one or more 
data points.  Of the 14, 11 were only missing one time point and data were imputed.  
Three children were missing more than one consecutive data point and were excluded 
from the analysis.  CDC growth percentiles were determined using Epi Info. and the date 
of the measurement was the exact age of the child at the missing time point.   
Formula Intake Data 
Formula intake and tolerance were assessed at each clinic visit through 12 months 
of age by querying the subject’s parent(s) or caregiver(s).  We asked questions about the 
amount of formula consumed, consumption of other formulas or milk, and bowel 
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movements describing the infant’s number, color, and consistency of stools for one day 
and any constipation, diarrhea, excess gas, or unusual fussiness.  See appendix C for 
formula intolerance collection form.  
Dietary Intake Data 
Dietary intake was assessed using a 24-hour recall collected from the parent(s) or 
caregiver(s) by registered dietitians trained by Dr. Debra Sullivan’s research team at the 
University of Kansas Medical Center at each clinic visit.  Foods and beverages consumed 
the day before the clinic visit (i.e. 12 A.M. to midnight the day prior) were recorded and 
included times of eating, portion sizes, and brand names and ingredients used in 
preparation.  Dietary intake was assessed using descriptions and tools of household 
measurements including measuring cups and spoons, pre-portioned bean bags of several 
amounts and sizes, labeled cups, and square, triangle, and circle shapes for sizes of foods.  
All tools had a reference chart to determine exact amounts.  See appendix D for the 24-
hour dietary recall collection form.  
Dietary information from all clinic visits was entered into the Nutrition Data 
System for Research (NDS-R)® software program (v4.06_34 University of Minnesota, 
Minneapolis, Minnesota) and exported to NDS-R®  version 2010 by a trained registered 
dietitian.  Average caloric intake was calculated for each subject and each formula group 
at each study visit between six weeks and six years of age.  Energy intake was entered 
and transferred into Microsoft Access and Microsoft Excel prior to analysis by IBM 
Statistical Package for the Social Sciences (SPSS)® 20.  We excluded 24-hour dietary 
recalls that were missing one or more meals or with kilocalories (kcal) less than 40 kcal 
per kilogram (kcal/kg) or greater than 200 kcal/kg.  Any recalls recorded as unreliable or 
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as non-typical were individually examined and were excluded with the same rules as 
stated above.  See appendix E for a list of omitted 24-hour dietary recalls.  
Training of Research Staff  
 The research staff and registered dietitians were trained to measure weight, 
length, height, and head circumference of infants and children by first obtaining 
measurements on staff to ensure reliability.  Registered dietitians then measured children 
with supervision, and after further approval, they collected data on children individually.  
They were also trained in conducting 24-hour dietary recalls using the Multiple Pass 
Method by first interviewing staff to ensure reliability (42).  The Multiple Pass Method 
used for 24-hour dietary recalls collected at the University of Kansas Medical Center 
consisted of first allowing the parent or guardian to list all foods and beverages eaten by 
the infant and child the day before the clinic visit with the interviewer using neutral 
probing questions.  Second, the interviewer asked for details on all foods and beverages 
listed.  Third, the interviewer reviewed the recall with the parent or guardian, probing for 
missing items (42).  Research staff and registered dietitians were also trained to use 
Nutrition Data System for Research (NDS-R)® to enter recalls for nutritional analyses.  
Staff entering dietary recalls into NDS-R® were required to reliably enter 12 
standardized 24-hour dietary recalls of hypothetical subjects ranging in age from six 
week to six years and were considered reliable if nutritional analyses were within five 
percent of nutrient levels when compared to master analyses.   
Collection and Analysis of Data  
 Data collected prospectively for each subject included DHA (yes, no), DHA 
amount (0, 0.32, 0.64, 0.96% DHA), weight, length, and head circumference (absolute 
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and percentiles for age) and energy intake at each study visit.  Maternal characteristics 
were determined by interviews and questionnaires.  Maternal data included self-reported 
maternal weight at enrollment, last clinic visit, and at delivery; height; education level; 
race and ethnicity; smoking status prior to and during pregnancy; the number of packs of 
cigarettes smoked per day and the number of pack years of smoking.  The data were 
entered into Microsoft Excel and transferred to IBM SPSS® Statistics 20 for statistical 
analyses.  For demographic characteristics, means and standard deviations were 
calculated.   
 The effect of DHA supplementation in formula fed during the first year of life 
and BMI from two to six years of age and individual anthropometric parameters (weight, 
length, weight z-scores, length z-scores, and weight-for-length percentiles from birth to 
two years of age) were initially analyzed using repeated measures analysis of variance 
(ANOVA).  Covariates included maternal smoking status and pack years smoked, 
maternal age, maternal education, and maternal BMI at enrollment.  Results were 
considered significant if the p value was less than 0.05.   
 It became clear that this analysis was not the correct analysis, because lines 
were parallel and not intersecting.  The repeated measures analysis dropped children who 
did not have all assessments as well.  A second analysis was completed with a former 
collaborator of Dr. Susan Carlson, Dr. Betsy Tolley, using a Statistical Analysis System 
(SAS) procedure that created a trajectory for weight, height, and BMI percentiles for each 
child.  The procedure allowed calculation of a median weight, height, BMI percentile, 
and energy intake for each group (DHA no, maternal smoking no; DHA yes, maternal 
smoking no; DHA no, maternal smoking yes; DHA yes, maternal smoking yes).  
24 
 
Additional variables tested were age (to determine if these variables were affected by 
increasing age between two and six years) and maternal BMI at the time the child’s 
mother became pregnant.  We did not test the effect of race because of the small number 
of degree of freedom (65).    
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Chapter 4 
Results 
The objectives of this thesis were to determine 1) if the concentration of DHA in 
formula consumed from birth to 12 months of age affects growth and particularly 
indicators of body fatness (weight-for-length and BMI-for-age) and 2) to determine if 
maternal smoking history affects these same indicators of growth and body fatness.  The 
specific study questions were refined to focus on weight, height, and BMI percentiles 
from two to six years of age, but some data are included on weight and length between 
birth and two years of age.  The CDC recommends using BMI-for-age percentiles after 
two years of age (18-21).  It is not possible to calculate weight-for-length percentiles for 
all children to six years of age, because a large number of children exceed the length that 
can be used in this calculation (121 cm).  Nevertheless, I included trajectories for 
absolute weight and length from birth to six years.  These figures are useful to 
demonstrate that children who were fed formula with and without DHA did not differ in 
weight or length at birth, though children whose mothers smoked during pregnancy were 
lighter and shorter through four years of age (shown previously by another Master’s of 
Science student, Nicole Kreber).   
Subject Characteristics  
Subject characteristics are shown in Table 1 for the original study population and 
the subset of subjects studied from birth through six years of age.  Maternal 
characteristics are shown for the original study population and the subset of subjects 
though six years of age in Table 2, and Table 3 shows maternal and infant characteristics 
of the study population supplemented and unsupplemented with DHA and ARA.  These 
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tables indicate the subset of subjects studied from birth to six years of age represents the 
original study population well, and results suggest the subgroup is similar to the original 
cohort except that more males than females were lost during the follow-up study.   
Table 1.  Infant characteristics of the original study subjects and the subset of  
study subjects. 
Infants  Original Study Population 
n=159 
Subset Study Population 
n=70 
Male [n (%)] 75 (47.2%) 23 (32.9%) 
Female [n (%)] 84 (52.8%) 47 (67.1%) 
Weight at birth (g)* 3380 ± 414 3424 ± 360 
Length at birth (cm)* 49.9 ± 2.09 50.01 ± 1.65 
Head circumference at birth (cm)* 33.91 ± 2.66 34.20 ± 1.32 
* Reported as mean ± standard deviation (SD). 
 
Table 2.  Maternal characteristics of the original study subjects and the subset of  
study subjects. 
Maternal Characteristics 
Original Study 
Population  
n=159 
Subset Study Population 
n=70 
Weight at 1
st
 clinic visit (lbs)* 165.06 ± 43.69 169.00 ± 43.23 
Height (inches)* 64.39 ± 2.87 64.17 ± 3.14 
BMI at 1
st
 clinic visit (kg/m
2
)* 27.90 ± 7.09 28.93 ± 7.06 
Weight at last clinic visit (lbs)* 186.36 ± 44.07 195.74 ± 44.30 
Weight at delivery (lbs)* 190.25 ± 42.25 197.07 ± 43.63 
Age at delivery (years)* 23.91 ± 5.39 23.46 ± 4.28 
Smoking before pregnancy [n (%)] 73 (45.9%) 33 (47.1%) 
Smoking during pregnancy [n (%)] 49 (30.8%) 24 (34.3%) 
Pack years smoked 
(packs per day x years smoked)* 
1.72 ± 3.35 1.89 ± 3.41 
Education obtained (years)* 12 ± 1.65 11.9 ± 1.47 
Race   
White 59 (37.1%) 24 (34.3%) 
Black/African American 98 (61.6%) 45 (64.3%) 
Other 2 (1.26%) 1 (1.4%) 
*Reported as mean ± standard deviation (SD). 
27 
 
Table 3.  Maternal and infant characteristics of the subset study population supplemented 
and unsupplemented with DHA and ARA.  
 
Infant Characteristics 
Unsupplemented 
Study Population 
n=16 
Supplemented 
Population 
n=54 
Male [n (%)] 6 (37.5%) 17 (31.5%) 
Female [n (%)] 10 (62.5%) 37 (68.5%) 
Weight at birth (g)* 3354 ± 394 3424 ± 360 
Length at birth (cm)* 49.6 ± 1.69 50.13 ± 1.64 
Head circumference at birth (cm)* 34.26 ± 1.4 34.19 ± 1.31 
Maternal Characteristics   
Weight at 1
st
 clinic visit (lbs)* 168.99 ± 46.95 169.01 ± 42.60 
Height (inches)* 63.93 ± 3.76 64.24 ± 2.97 
BMI at 1
st
 clinic visit (kg/m
2
)* 29.12 ± 7.33 28.88 ± 7.05 
Weight at last clinic visit (lbs)* 201.69 ± 53.06 193.76 ± 41.58 
Weight at delivery (lbs)* 203.33 ± 52.92 194.78 ± 40.22 
Age at delivery (years)* 22.75 ± 3.96 23.67 ± 4.39 
Smoking before pregnancy [n (%)] 8 (50.0%) 25 (46.3%) 
Smoking during pregnancy [n (%)] 4 (25.0%) 20 (37.0%) 
Pack years smoked  
(packs per day  x  years smoked)* 
1.52 ± 2.37 1.89 ± 3.41 
Education obtained (years)* 12.0 ± 1.71 11.9 ± 1.41 
Race [n(%)]   
     White  2 (12.5%) 22 (40.7%) 
     Black/African American 14 (87.5%) 31 (57.4%) 
     Other 0 1 (1.9%) 
*Reported as mean ± standard deviation (SD). 
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Effects of DHA and maternal smoking on BMI of children  
Initial analyses were conducted using repeated measures analysis of variance 
(ANOVA).  As noted previously, the n for these analyses is smaller than the available 
children in each group.  All DHA supplemented groups (n=52; [0.32% DHA (n=15)], 
[0.64% DHA (n=16)], [0.96% DHA (n=23)]) were combined and compared to the control 
group without DHA supplementation (n=15).  Covariates that were evaluated in the 
analyses were maternal BMI at enrollment, maternal education, and maternal smoking 
status and pack years [smoking (n=22) vs. non-smoking (n=45)].   
 A secondary analysis was conducted using Least Squares Means (LSM) and 
evaluated weight, length, BMI, and energy intake from two to six years of age.  The 
covariates that were shown to be influential in the ANOVA were evaluated for 
significance (Table 4).  Based on this analysis, maternal education and maternal BMI at 
enrollment, which trended toward significance, were not chosen for inclusion in the LSM 
analysis.  DHA supplementation status, maternal smoking during pregnancy (yes or no), 
and child age were included in the LSM analysis.     
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Table 4. Evaluation of potential covariates in the analyses of the effect of DHA 
supplementation on growth of children.** 
 Weight Percentile BMI 
DHA supplementation  0.0045* 0.4597 
Child Age 0.5958 0.0363* 
   
DHA supplementation  0.0070* 0.4136 
Child Age 0.5950 0.0370* 
Maternal education  0.2002 0.4320 
   
DHA supplementation  0.0196* 0.4976 
Child Age 0.6275 0.0444* 
Maternal BMI at enrollment 0.9203 0.0700 
   
DHA supplementation 0.0088* 0.4133 
Child Age 0.5971 0.0350* 
Smoking pack years 0.1375 0.5319 
   
DHA supplementation  0.0056* 0.4103 
Child Age 0.6001 0.0348* 
Smoker 0.6517 0.4637 
   
DHA supplementation  0.0322* 0.4439 
Child Age 0.5593 0.0392* 
Smoking during pregnancy 
(ppd) 
<0.0001* 0.7657 
   
DHA supplementation  0.0179* 0.519 
Child Age 0.5265 0.0205* 
Smoking during pregnancy <0.0001* 0.1175 
DHA supplementation * 
Smoking during pregnancy  
0.3898 0.6227 
*Indicates significance (p≤0.05). 
**LSM. 
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Measures of BMI 
The mean BMI and mean BMI percentiles were analyzed in DHA supplemented 
and unsupplemented children from two to six years of age.  Results are illustrated in 
Figure 1 and Figure 2, respectively.   
In children two to six years of age, maternal BMI at enrollment positively 
influenced the child’s BMI (p=0.0700), though it did not quite reach significance.  DHA 
supplementation resulted in an overall BMI from two to six years of age that was 0.23 
units higher compared to formula without DHA and ARA, but the difference was not 
significant (p=0.4976).  However, for every one year increase in age between two and six 
years of age, children’s BMI increased by 0.20 (p=0.0444).  Table 5 illustrates the effects 
of DHA supplementation on BMI of children through six years of age.   
BMI-for-age percentiles of children from two to six years of age were not 
influenced by DHA supplementation (p=0.1723).  Maternal smoking during pregnancy 
increased children’s BMI percentiles by 23% compared to children of women who did 
not smoke during pregnancy (p<0.0001).  There was no interaction between DHA 
supplementation and maternal smoking during pregnancy.  Age positively influenced 
BMI percentiles as BMI percentiles increased by 6.5 percentiles every year from two to 
six years (p<0.0001).  Table 6 illustrates the effects of all variables on BMI percentiles of 
children through six years of age. 
We assessed how many children became overweight or obese according to BMI-
for-age percentiles from two to six years of age.  The American Academy of Pediatrics 
ask pediatricians to counsel families of children who become overweight (85-95
th
 
percentile of BMI-for-age percentiles) or obese (>95
th
 percentile of BMI-for-age 
31 
 
percentiles) to encourage them to achieve a healthy weight by reducing energy intake and 
increasing energy expenditure (43).  The CDC growth percentiles change, and after two 
years of age, weight-for-length percentiles cannot be calculated.  As noted previously 
(13), the weight-for-length percentiles at two years of age are higher than the BMI 
percentiles.  This is the most likely reason for the apparent reduction in overweight and 
obese children between 18 months and two years of age.  We examined the number of 
children who were overweight and obese from two to six years of age in the cohort.  This 
resulted in a high number of overweight and obese children starting at age four and 
continuing through age six.  Results are illustrated in Tables 7.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. BMI from two to six years of age in DHA supplemented and unsupplemented 
children. 
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Figure 2. BMI-for-age percentiles from two to six years of age in supplemented and 
unsupplemented children.   
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Table 5. Effects of DHA supplementation, age, and maternal BMI on BMI of children 
through 6 years of age.* 
*LSM. 
 
Table 6. Effects of DHA supplementation and maternal smoking on BMI percentiles of 
children through 6 years of age.* 
 
 
 
 
 
 
 
 
 
*LSM. 
 
 
 
 
 
 
 
 
 Estimate Standard 
Error 
Degrees 
Freedom 
T Value P Value 
Intercept 16.9368 0.5617 64 30.15 <0.0001 
DHA 
supplementation 
0.2278 0.3340 64 0.68 0.4976 
Age of child 0.1984 0.09680 66 2.05 0.0444 
Maternal BMI at 
enrollment 
0.03387 0.01865 460 1.82 0.0700 
Final Model Estimate Standard 
Error 
Degrees 
Freedom 
P Value 
DHA Supplementation  7.0091 5.0787 65 0.1723 
Smoking (pregnancy) 23.0340 5.0787 65 <0.0001 
 
 Estimate Standard 
Error 
Degrees 
Freedom 
T Value P Value 
Intercept 58.6771 3.4017 65 17.25 <0.0001 
DHA 
supplementation 
14.5068 8.9185 65 1.63 0.1087 
Age 6.4874 0.6523 68 9.94 <0.0001 
Smoking (pregnancy) 30.5317 4.0729 65 7.50 <0.0001 
DHA * Smoking 
(pregnancy) 
14.9955 10.1573 65 1.48 0.1447 
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Age 85
th
 - 95
th
%, n(%) >95
th
%, n(%) 
Birth 3 (4%) 5 (7%) 
6 weeks 8 (11%) 3 (4%) 
4 months 9 (13%) 4 (6%) 
6 months 6 (9%) 5 (7%) 
9 months 12 (17%) 5 (7%) 
12 months 11 (16%) 4 (6%) 
18 months 10 (14%) 4 (6%) 
2 year 4 (6%) 3 (4%) 
2.5 year 10 (14%) 3 (4%) 
3 year 5 (7%) 7 (10%) 
3.5 year 12 (17%) 8 (11%) 
4 year 18 (26%) 11 (16%) 
4.5 year 12 (17%) 15 (21%) 
5 year 11 (16%) 15 (21%) 
5.5 year 17 (24%) 13 (19%) 
6 year 11 (16%) 15 (21%) 
 
Table 7.  Overweight and obese children according to weight-for-length percentiles     
(birth to 2 years) and BMI-for-age percentiles (2 to 6 years) (n=70). 
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Measures of Weight 
The mean weights of subjects who consumed DHA supplemented formulas and 
the unsupplemented formula was compared from birth through six years.  Weight was 
significantly higher from six weeks through six years of age in subjects who consumed 
the DHA supplemented formulas compared to those unsupplemented (p=0.038).  
Maternal education, a measure of socioeconomic status, was positively related to weight 
of children to six years of age (p=0.006), and maternal BMI was also positively related to 
weight of children (p=0.007).  Results are illustrated in Figure 3.   
DHA supplementation positively influenced weight z-scores from birth to six 
years of age (p=0.048) after correcting for covariates of maternal BMI at enrollment 
(p=0.007), maternal education (p=0.043), and maternal smoking pack years (p=0.400).  
Results are illustrated in Figure 4.   
A second analysis that created a weight percentile trajectory for each child 
showed that DHA supplemented children had significantly higher weight percentiles than 
unsupplemented children (p=0.0179).  Maternal smoking during pregnancy had an even 
more pronounced influence on weight percentiles with smoking related to a 32% increase 
in weight percentile (p<0.0001).  When children born to mothers who smoked during 
pregnancy but who received DHA were compared to children whose mother did not 
smoke but who also received DHA, the weight percentiles were 91.9 compared to 53.9 
mean percentile, respectively (p<0.0001).  Likewise, among children who did not receive 
DHA, weight percentiles were higher in those whose mother’s smoked during pregnancy 
compared to those whose mother’s did not (69.7 and 43.4 mean percentiles, respectively, 
p=0.0369).  The group of children with the lowest weight percentiles (43.4) was those 
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who did not receive DHA and had mothers who did not smoke.  Table 8 illustrates the 
effects of DHA supplementation on weight percentiles of children through six years of 
age and includes the mean percentiles for the different DHA and smoking combinations.   
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Figure 3. Weight (kg) from birth to six years in DHA supplemented and unsupplemented 
children.  Independent effects of maternal education, maternal BMI at enrollment, and 
maternal smoking pack years were observed and adjusted for in the figure.   
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Figure 4. Weight z-scores from birth to six years in DHA supplemented and 
unsupplemented children.   
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 Table 8.  Effects of DHA supplementation on weight percentiles of children through 6 
years of age.* 
  
*LSM.  
 
 
 
 
Effect Estimate Standard 
Error 
Degrees 
Freedom 
No DHA supplementation 56.5410 10.3084 65 
DHA supplementation 72.9234 8.6806 65 
No smoking (pregnancy) 48.6473 8.8553 65 
Smoking (pregnancy) 80.8172 10.1587 65 
No DHA * No smoking 
(pregnancy) 
43.3759 9.9344 65 
No DHA * Smoking 
(pregnancy) 
69.7062 13.7920 65 
DHA * No smoking 
(pregnancy) 
53.9187 8.8805 65 
DHA * Smoking 
(pregnancy) 
91.9281 9.2965 65 
 Estimate Standard 
Error 
Degrees 
Freedom 
F Value P Value 
Intercept 86.2924 4.3267 65 19.94 <0.0001 
DHA Supplementation 22.2219 11.8531 65 1.87 0.0653 
Age 1.4075 2.2108 68 0.64 0.5265 
Smoking (pregnancy) 38.0094 5.4005 65 7.04 <0.0001 
DHA * Smoking 
(pregnancy) 
11.6790 13.4885 65 0.87 0.3898 
Final Model Estimate Standard Error T Value P Value 
DHA Supplementation  16.3824 6.7443 2.43 0.0179 
Smoking (pregnancy) 32.1699 6.7443 4.77 <0.0001 
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Measures of Length/Height   
When analyzing the mean length/height of children, DHA supplementation did 
not appear to influence height to six years of age (p=0.137).  However, maternal 
education was positively related to height from four months through six years (p=0.024).  
Results are illustrated in Figure 5.  DHA supplementation did not influence length z-
scores from birth to six years of age (p=0.096), nor did maternal BMI at enrollment 
(p=0.054), maternal education (p=0.166), or maternal pack years smoked (p=0.662).  
Results are illustrated in Figure 6.   
A second analysis that calculated a height trajectory from two to six years of age 
for each child demonstrated that children supplemented with DHA were significantly 
taller than unsupplemented children (p=0.0039).  Children of women who smoked during 
pregnancy were 17.6% taller than children born to nonsmoking mothers (p=0.0006).  No 
interaction was found between DHA and maternal smoking during pregnancy 
(p=0.3745).  Results are shown in Table 9.  Table 10 summarizes the least squares mean 
weight, height, and BMI percentiles for children two to six years of age by DHA and 
maternal smoking. 
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Figure 5. Length/Height (cm) from birth to six years in DHA supplemented and 
unsupplemented children.  Independent effects of maternal education was observed and 
adjusted for in the figure.  
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 Estimate 
Standard 
Error 
Degrees 
Freedom 
T Value P Value 
Intercept 92.0199 3.1379 65 29.33 <0.0001 
DHA 
Supplementation 
18.9377 8.5536 65 2.21 0.0303 
Age of child -3.5036 0.6694 68 -5.23 <0.0001 
Smoking (pregnancy) 21.9615 3.9092 65 5.62 <0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Length/Height (cm) z-scores from birth to six years in DHA supplemented and 
unsupplemented children. 
 
Table 9.  Effects of DHA supplementation on height percentiles of children through 6 
years of age.* 
 
 
 
 
 
 
 
 
 
 
*LSM. 
 
 
Final Model Estimate Standard Error T Value P Value 
DHA Supplementation 14.5810 4.8720 2.99 0.0039 
Smoking (pregnancy) 17.6048 4.8720 3.61 0.0006 
 
42 
 
Table 10.  Effects of DHA and smoking during pregnancy on weight, height, and BMI 
percentiles for children two to six years of age.* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentile Estimate Standard Error 
BMI Percentiles    
DHA supplementation 7.0091 5.0787 
Smoking (pregnancy) 23.0340 5.0787 
No DHA * No smoking (pregnancy) 54.6048 4.4560 
No DHA * Smoking (pregnancy) 70.1410 8.4572 
DHA * No smoking (pregnancy) 54.1161 2.9215 
DHA * Smoking (pregnancy) 84.6478 3.5823 
Weight Percentiles   
DHA supplementation 16.3824 6.7443 
Smoking (pregnancy) 32.1699 6.7443 
No DHA * No smoking (pregnancy) 43.3759 9.9344 
No DHA * Smoking (pregnancy) 69.7062 13.7920 
DHA * No smoking (pregnancy) 53.9187 8.8805 
DHA * Smoking (pregnancy) 91.9281 9.2965 
Height Percentiles   
DHA supplementation 14.5810 4.8720 
Smoking (pregnancy) 17.6048 4.8720 
No DHA * No smoking (pregnancy) 45.8080 4.5738 
No DHA * Smoking (pregnancy) 59.0562 8.2713 
DHA * No smoking (pregnancy) 56.0324 3.2375 
DHA * Smoking (pregnancy) 77.9939 3.8004 
*LSM.  
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Energy Intake  
Average energy intakes (kcal) from 24-hour dietary recalls were generated for 
each age and formula group (Table 11).  An analysis of energy intake from two to six 
years found no effect of DHA supplementation (p=0.7081), maternal smoking during 
pregnancy (p=0.8603), or age (p=0.3784).  Results are illustrated in Table 12.  
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Table 12.  Influence of DHA and smoking during pregnancy on energy intake in children 
from two to six years of age.* 
 
 
 
 
 
 
 
      *LSM. 
 
 
 
 
 
 
 
 
 
 
 
 Estimate Standard 
Error 
Degrees 
Freedom 
T Value P Value 
DHA Supplementation -38.9574 103.59 65 -0.38 0.7081 
Smoking (pregnancy) 18.2988 103.59 65 -0.18 0.8603 
Age -14.6563 16.5315 65 -0.89 0.3784 
 
Energy Intake Estimate Standard Error 
DHA supplementation  1512.25 43.5024 
Smoking (pregnancy) 1540.88 91.8023 
No DHA * No smoking (pregnancy) 1530.79 86.3579 
No DHA * Smoking (pregnancy) 1571.62 169.92 
DHA * No smoking (pregnancy) 1514.36 52.5392 
DHA * Smoking (pregnancy) 1510.13 67.0465 
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Chapter 5 
Discussion 
This study finds higher weight and height but not higher BMI of children 
supplemented with DHA, which contrast with previously reported findings that no 
differences exist in growth of term infants fed DHA supplemented formula (7-12).  One 
study did find a higher BMI (p<0.022) among children at 2.5 years of age whose mothers 
were given a fish oil supplement compared to mothers given an olive oil supplement 
during lactation (0 to 4 months of lactation), but no differences were found in weight, 
length, or head circumference through 9 months of age (44).  Another study found infants 
on a fish oil supplement from nine to 18 months of age had lower skinfold ratios at 18 
months than infants fed a sunflower oil supplement (p=0.02) (45).   
Previous research has not analyzed the growth of term infants fed DHA 
supplemented formulas through six years of age, rather only through 39 months (11).  
The length of time infants were fed DHA supplemented formula differed among studies, 
ranging from four months to one year of age (7-12).  The source of DHA and ARA also 
varied among previous studies (egg yolk, fish oil, soy oil, coconut oil, or high oleic 
sunflower oil).  In addition, other studies have compared formulas with different 
percentages of DHA, DHA and ARA, and no DHA and ARA (7-12).  We fed three 
different concentrations of DHA with a fixed amount of ARA in formula to term infants, 
which contained higher DHA and ARA concentrations, excluding the control formula, 
than earlier studies had used.  Because there was no effect of DHA and ARA dose on 
child growth, the analysis collapsed all children who received DHA and ARA 
supplementation and compared them to children who did not receive any 
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supplementation (13).  These may be contributing factors as to why our results contrast 
with existing research.  Another factor may be that differences in weight and length 
appear to emerge around two years of age.  By following children from two to six years, 
when BMI increases progressively, we may have been able to better identify effects of 
both smoking and DHA and ARA supplementation.  Finally, United States children may 
be more overweight and obese than in other countries, which could allow environmental 
effects to emerge.   
An examination of the effects of maternal smoking status clearly shows that 
maternal smoking during pregnancy is related to higher child weight and length and also 
higher BMI, which implies increased body fatness.  In contrast to DHA, which increased 
both weight and length but not BMI percentiles, the increase in weight percentiles with 
maternal smoking was greater than the increase in length percentiles.  It is this difference 
that resulted in a significant increase in BMI for children of women who smoked.  An 
earlier examination of growth in this cohort showed that children of smoking women 
were shorter and lighter at birth and more likely to be overweight and obese by four years 
of age (13).  Another study found that maternal smoking had a negative effect on length 
when term infants were fed DHA and ARA supplemented formulas for one year, 
suggesting maternal smoking has a more influential role in growth than DHA and ARA 
supplementation (7).  The impact of maternal smoking status on children has been shown 
to result in shorter infants at birth and shorter children to age eight, which contrasts with 
our findings but are consistent with previous reports from several studies that indicate 
maternal smoking during gestation increases a child’s risk of becoming overweight or 
obese later in life (29-31, 33).   
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A high percentage of women enrolled in the study had smoked before pregnancy 
[n=73 (45.9%)] and/or smoked during pregnancy [n=49 (30.8%)].  In the subset 
population studied, the percentage of women who smoked before and/or during 
pregnancy remained high [smoked before pregnancy, n=33 (47.1%) and smoked during 
pregnancy, n=24 (34.3%)], which provided a large enough number to reasonably evaluate 
the effect of smoking during pregnancy.   
Our data for overweight and obesity indicate slightly higher incidences than the 
CDC’s Pediatric Nutrition Surveillance System (PedNSS) 2008 report, which shows a 
14.6% prevalence of childhood obesity in low-income, preschool aged children through 
four years of age (46).  By age four, 23.4% of the children in our cohort were overweight 
and 15.6% were obese.   
From the analysis of energy consumed by each formula group by gender, no 
significance resulted at any age.  Therefore, gender was not a factor in energy consumed; 
Maternal education, maternal BMI, and DHA supplementation in formula consumed for 
one year of life positively influence weight of children through six years of age but not 
energy intake.  The trend toward higher child BMI is similar to previous findings that 
mothers who are overweight are more likely to have overweight children (17).   
Limitations 
A limitation of this study was the small number of subjects in the unsupplemented 
DHA group compared to the subjects fed one of three DHA supplemented formulas 
(n=15 and 54, respectively).  Because there was no effect of DHA and ARA dose on 
child growth, all DHA supplemented groups were combined (13).  The combination of 
DHA supplemented children compared to unsupplemented children resulted in an uneven 
49 
 
subject number.  This could have resulted in a Type 2 error, in particular finding that 
supplemented children did not have higher BMI-for-age percentiles than those who were 
not supplemented, when in fact a larger group may have shown an effect on BMI-for-age 
percentiles.  The fact that DHA supplementation increased weight and length percentiles, 
despite the low number of control, suggests that the effect size on growth is quite large, 
although a Type 1 error cannot be ruled out.   
 Another limitation was the disproportional distribution of race in the control and 
supplemented groups.  The DHA supplemented children were similarly represented by 
white and black/African American races, but the distribution of race in unsupplemented 
children included more black/African American subjects.  There were also more female 
than male children who completed the study, which could have influenced absolute 
growth.  However, the CDC percentiles for weight, height, and BMI that served as a basis 
for the main study questions do account for gender differences.  
The 24-hour dietary recalls and questions concerning formula intake and tolerance 
are self-reported and subjective, allowing for error.  Over or under estimation of 
individual dietary intake may have occurred by the caregiver(s) or guardian(s) due to 
distortions in portion sizes eaten by infants, toddlers, and young children and due to 
children spending time outside of a parent’s care.  In addition, growth and development is 
not only related to DHA supplementation and maternal smoking status, but it is also 
related to dietary factors including the type and amount of formula consumed, type and 
time point of introduction of solid foods to infants and toddlers, and quality of the diet.  It 
is also influenced by genetics.  
50 
 
The weight-for-length percentiles cannot reliably be used after age four because 
children who achieve a length greater than 121 centimeters are omitted.  This is one of 
the reasons we chose BMI-for-age percentiles to represent body fatness from two to six 
years of age.  The weight-for-length percentiles do not illustrate groups reliably until four 
years.   
Future Studies  
It has been established that preterm infants fed a formula supplemented with DHA 
improves growth of these infants (2, 5, 6).  Of the published studies on the growth of term 
infants fed DHA supplemented formula, none find any differences in weight or length (7-
12).  However, when DHA is supplemented to the mother during lactation, a child’s BMI 
increases, and if fish oil is supplemented to the infant, lower skinfold ratios result (44, 
45).  Further analyzing children through school age, specifically from two to six years of 
age could help identify the environmental conditions that contribute to a yearly increase 
in BMI and that could contribute to their risk of becoming overweight or obese.  
Identifying these risks could also lead to interventions.     
Although we looked only at energy intake, it is feasible that the diet of children of 
women who smoke during pregnancy differs in quality.  This could contribute to 
differences in body composition, particularly to increased body fatness.  It would be 
worthwhile to evaluate the diet quality of children in this study by maternal smoking 
during pregnancy as there may be differences in childhood feeding practices between 
smokers and nonsmokers, further programming a child’s growth.  If this is not the case, 
one might more strongly consider some physiological, endocrine, or motivational 
changes caused by maternal smoking exposure during fetal life.  
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Studies to evaluate body composition using more sophisticated analyses (e.g., 
assessment of body composition by air displacement plethysmography (ADP)) could be 
valuable additions to the literature related to maternal smoking.   
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Chapter 6 
Summary 
Docosahexaenoic acid (DHA) is a long chain omega-3 polyunsaturated fatty acid 
essential for visual, cognitive, and central nervous system development in infants (1, 2).  
DHA was added to infant formulas in the United States in 2002 (3).  Studies have 
investigated the effects of formula supplemented with DHA on weight and body mass 
index (BMI) of children, but results are mixed.  Three studies indicate DHA-
supplemented formula fed to preterm infants improves weight gain (2, 5, 6).  Six studies 
report the effects of DHA-supplemented formula fed to term infants and find no 
differences in weight or length (7-12).    
This study was a double-blind, 2-phase, randomized, controlled, parallel-group, 
prospective trial.  The primary outcome of the study was to determine the effects of DHA 
and ARA supplementation in formula on visual evoked potential acuity of infants.  For 
the purposes of this thesis project, the outcomes were to determine 1) if the concentration 
of DHA in formula (0, 0.32%, 0.64%, 0.96% of the total fatty acids from DHA) 
consumed from birth to 12 months of age affects growth (BMI-for-age percentiles) and 2) 
to determine if maternal smoking history affects the same indicator of growth and body 
fatness of children through six years.  All DHA supplemented groups (n=52; 0.32%, 
0.64%, 0.96% DHA) were combined and compared to the control group with no DHA 
supplementation after group differences among the DHA groups were not found.   
Between two and six years of age, DHA supplementation increased both weight-
for-age and height-for-age percentiles in children but not BMI-for-age percentiles, 
whereas maternal smoking during pregnancy increased weight, height, and BMI 
53 
 
percentiles. DHA supplementation resulted in an overall BMI that was 0.23 units higher 
compared to formula without DHA and ARA, and maternal BMI at enrollment positively 
influenced the child’s BMI, though neither reached significance.  However, maternal 
smoking during pregnancy significantly increased children’s BMI percentiles by 23% 
compared to children of women who did not smoke during pregnancy.  There was no 
interaction between DHA supplementation and maternal smoking during pregnancy on 
children’s BMI-for-age percentiles.   
Maternal smoking during pregnancy had an even more pronounced influence on 
weight percentiles with smoking related to a 38% increase in weight percentile 
(p<0.0001).  When children born to mothers who smoked during pregnancy but who 
received DHA were compared to children whose mother did not smoke but who also 
received DHA, the weight percentiles were significantly higher.  The group of children 
with the lowest weight percentiles was those who did not receive DHA and had mothers 
who did not smoke.  Children supplemented with DHA were significantly taller than 
unsupplemented children by 19 percentiles, but children of women who smoked during 
pregnancy were also significantly taller (22 percentiles) than children born to 
nonsmoking mothers.  Energy intake was not related to either DHA intake or maternal 
smoking during pregnancy, suggesting the effects were unrelated to differences in energy 
intake.   
Further research is warranted to determine the most beneficial amount of DHA 
supplemented in formula fed to term infants from birth through 12 months of age and the 
effects on the long term growth of children.  Additional research is needed to determine a 
more specific critical time point in which children may become overweight or obese later 
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in life, as well as the body composition of children in relation to DHA and maternal 
smoking.   
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Appendix A 
Subjects Demographic Data Collection Form 
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 INVESTIGATOR PROTOCOL  RANDOM CODE  DATE 
 CARLSON HSC #10205       
           
DEMOGRAPHICS 
           
Maternal 
Education         
           
Paternal 
Education         
           
Does anyone living in the child's home smoke?      
 No Yes
 If yes, how many people smoke & how many ppd?  
__________________ 
List any maternal allergies: 
_________________________________________________________________ 
Including the child enrolled in this study, how many children 13 years of age or younger live in your 
house? 
 1    2    3    4    5    6 or more
Do any pets live in the child's home?       
 No Yes  If yes, how many pets?  __________________________ 
  
  What kind? 
________________________________________________ 
Do you take your child to a daycare (facility or homecare) with other infants and children? 
 No        
 Yes, with 1 to 5 children       
 Yes, with 6 to 10 children       
 Yes, with more than 10 children      
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Appendix B 
Anthropometric Data Collection Form 
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INVESTIGATOR PROTOCOL 
 
INITIALS 
 
RANDOM CODE 
 
DOB 
 
CARLSON HSC #10205 
 
  
 
  
 
  
           ANTHROPOMETRICS 
           
 
2 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                
           
 
2.5 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                
           
 
3 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                
           
 
3.5 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                
           
 
4 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                
 
63 
 
 
INVESTIGATOR PROTOCOL 
 
INITIALS 
 
RANDOM CODE 
 
DOB 
 
CARLSON HSC #10205 
 
  
 
  
 
  
           
ANTHROPOMETRICS PAGE 2 
           
 
4.5 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                      
           
 
5 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                      
           
 
5.5 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
                      
           
 
6 Year Visit 
 
Weight 
  
  g 
 
 
  
    
  
  
 
      
 
Length 
  
  cm 
 
MO DA YEAR 
    
  
  
     
Head circumference 
 
  cm 
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Appendix C 
Formula Tolerance Collection Form 
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Appendix D 
24-Hour Dietary Recall Collection Form 
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24-Hour Dietary Recall Form 
Visit:_________         
          
Random 
#___________________ 
   Date of 
Intake:____________ DOB:___________ EDC:__________ 
          
Time Food/Beverage Ingredients/Preparation Amount 
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
          
Intake: Typical      More than Usual          Less than Usual         Why? _______________________________ 
_________________________________________________________________________________________ 
Recall:  Reliable     Unable to recall meals?  Unreliable for other reasons?  Why? _______________________ 
_________________________________________________________________________________________ 
          
Vitamin/Mineral/Supplement Use?  __________________________________________________________ 
          
Home / Daycare / Babysitter                          Number of people responsible for feeding _______________ 
          
       Interviewer Initials: _______ 
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Appendix E 
List of Omitted 24-Hour Dietary Recalls  
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Unable to recall one or more meals: 95 total 
Subject 139 at 4 months 
 
Subject 87 at 6 months 
 
Subject 80 at 9 months 
 
Subject 74 at 12 months 
Subject 124 at 12 months 
 
Subject 2 at 18 months 
Subject 46 at 18 months 
Subject 60 at 18 months 
Subject 84 at 18 months 
Subject 89 at 18 months 
Subject 91 at 18 months 
Subject 125 at 18 months 
 
Subject 5 at 2 years 
Subject 24 at 2 years 
Subject 35 at 2 years 
Subject 43 at 2 years 
Subject 62 at 2 years 
Subject 102 at 2 years 
Subject 103 at 2 years 
 
Subject 9 at 2.5 years 
Subject 139 at 2.5 years 
 
Subject 103 at 3 years 
 
Subject 46 at 3.5 years 
Subject 108 at 3.5 years 
Subject 127 at 3.5 years 
 
Subject 97 at 4 years 
Subject 102 at 4 years 
Subject 135 at 4 years 
Subject 148 at 4 years 
Subject 154 at 4 years 
 
Subject 32 at 4.5 years 
Subject 48 at 4.5 years 
Subject 102 at 4.5 years 
Subject 110 at 4.5 years 
Subject 112 at 4.5 years 
Subject 120 at 4.5 years 
Subject 131 at 4.5 years 
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Subject 35 at 5 years 
Subject 48 at 5 years 
Subject 75 at 5 years 
Subject 77 at 5 years 
Subject 88 at 5 years 
Subject 100 at 5 years 
Subject 112 at 5 years 
Subject 113 at 5 years 
Subject 120 at 5 years 
Subject 124 at 5 years 
Subject 131 at 5 years 
Subject 134 at 5 years 
 
Subject 11 at 5.5 years 
Subject 17 at 5.5 years 
Subject 24 at 5.5 years 
Subject 35 at 5.5 years 
Subject 39 at 5.5 years 
Subject 48 at 5.5 years 
Subject 60 at 5.5 years 
Subject 61 at 5.5 years 
Subject 74 at 5.5 years 
Subject 77 at 5.5 years 
Subject 80 at 5.5 years 
Subject 84 at 5.5 years 
Subject 113 at 5.5 years 
Subject 134 at 5.5 years 
Subject 139 at 5.5 years 
Subject 147 at 5.5 years 
Subject 149 at 5.5 years 
Subject 154 at 5.5 years 
Subject 155 at 5.5 years 
Subject 159 at 5.5 years  
 
Subject 5 at 6 years 
Subject 11 at 6 years 
Subject 13 at 6 years 
Subject 24 at 6 years 
Subject 30 at 6 years 
Subject 32 at 6 years 
Subject 39 at 6 years 
Subject 48 at 6 years 
Subject 60 at 6 years 
Subject 61 at 6 years 
Subject 77 at 6 years 
Subject 84 at 6 years 
Subject 87 at 6 years 
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Subject 96 at 6 years 
Subject 100 at 6 years 
Subject 102 at 6 years 
Subject 108 at 6 years 
Subject 113 at 6 years 
Subject 124 at 6 years 
Subject 126 at 6 years 
Subject 127 at 6 years 
Subject 134 at 6 years 
Subject 135 at 6 years 
Subject 154 at 6 years 
Subject 155 at 6 years 
Subject 158 at 6 years 
 
Over reporting (>200 kcals/kg):_23 total  
Subject 9 at 6 weeks  
Subject 85 at 6 weeks 
Subject 122 at 6 weeks 
Subject 125 at 6 weeks 
Subject 140 at 6 weeks 
 
Subject 50 at 6 months 
Subject 149 at 6 months 
 
Subject 17 at 9 months 
Subject 101 at 9 months  
 
Subject 59 at 12 months 
Subject 95 at 12 months 
 
Subject 4 at 18 months 
Subject 19 at 18 months 
Subject 98 at 18 months 
Subject 120 at 18 months  
Subject 121 at 18 months 
Subject 147 at 18 months  
 
Subject 88 at 2 years 
Subject 120 at 2 years 
Subject 143 at 2 years 
Subject 147 at 2 years  
 
Subject 97 at 2.5 years 
Subject 108 at 2.5 years 
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Underreporting (<40 kcal/kg):_54 total 
Subject 118 at 6 months 
 
Subject 54 at 9 months 
 
Subject 42 at 12 months 
Subject 118 at 12 months 
 
Subject 87 at 18 months 
Subject 89 at 18 months 
 
Subject 35 at 2 years 
 
Subject 9 at 4 years 
Subject 46 at 4 years 
Subject 97 at 4 years  
 
Subject 9 at 4.5 years 
Subject 32 at 4.5 years 
Subject 48 at 4.5 years 
Subject 62 at 4.5 years 
Subject 110 at 4.5 years 
Subject 112 at 4.5 years 
 
Subject 35 at 5 years 
Subject 77 at 5 years 
Subject 97 at 5 years 
Subject 112 at 5 years 
Subject 134 at 5 years  
 
Subject 5 at 5.5 years 
Subject 9 at 5.5 years 
Subject 11 at 5.5 years  
Subject 17 at 5.5 years 
Subject 35 at 5.5 years 
Subject 39 at 5.5 years 
Subject 46 at 5.5 years 
Subject 48 at 5.5 years 
Subject 63 at 5.5 years 
Subject 84 at 5.5 years  
Subject 97 at 5.5 years 
Subject 113 at 5.5 years 
Subject 131 at 5.5 years 
Subject 139 at 5.5 years 
Subject 149 at 5.5 years 
Subject 155 at 5.5 years 
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Subject 159 at 5.5 years  
 
Subject 5 at 6 years  
Subject 9 at 6 years 
Subject 48 at 6 years 
Subject 61 at 6 years 
Subject 62 at 6 years 
Subject 77 at 6 years 
Subject 84 at 6 years 
Subject 88 at 6 years 
Subject 97 at 6 years 
Subject 102 at 6 years 
Subject 109 at 6 years 
Subject 127 at 6 years 
Subject 139 at 6 years 
Subject 147 at 6 years 
Subject 154 at 6 years 
Subject 155 at 6 years
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Appendix F 
Parent Study Consent Form: Birth to 18 Months of Age 
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Appendix G 
Parent Study Consent Form: 2 to 6 Years of Age 
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